Top

BMC Infectious Diseases

Published in:

Open Access 01-12-2014 | Research article

Timing, rates, and causes of death in a large South African tuberculosis programme

Authors: Nigel Field, Megan SC Lim, Jill Murray, Robert J Dowdeswell, Judith R Glynn, Pam Sonnenberg

Published in: BMC Infectious Diseases | Issue 1/2014

Abstract

Background

Tuberculosis (TB) mortality remains high across sub-Saharan Africa despite integration of TB and HIV/ART programmes. To inform programme design and service delivery, we estimated mortality by time from starting TB treatment.

Methods

Routinely collected data on TB treatment, vital status, and the timing and causes of death, were linked to cardio-respiratory autopsy data, from 1995–2008, from a cohort of male platinum miners in South Africa. Records were expanded into person-months at risk (pm).

Results

4162 TB episodes were registered; 3170 men were treated for the first time and 833 men underwent retreatment. Overall, 509 men died, with a case fatality of 12.2% and mortality rate of 2.0/100 pm. Mortality was highest in the first month after starting TB treatment for first (2.3/100 pm) and retreatment episodes (4.8/100 pm). When stratified by HIV status, case fatality was higher in HIV positive men not on ART (first episode 14.0%; retreatment episode 26.2%) and those on ART (12.0%; 22.0%) than men of negative or unknown HIV status (2.6%; 3.6%). Mortality was also highest in the first month for each of these groups. Mortality risk factors included older age, previous TB, HIV, pulmonary TB, and diagnostic uncertainty. The proportion of deaths attributable to TB was consistently overestimated in clinical records versus cardio-respiratory autopsy.

Conclusions

Programme mortality was highest in those with HIV and during the first month of TB treatment in all groups, and many deaths were not caused by TB. Resource allocation should prioritise TB prevention and accurate earlier diagnosis, recognise the role of HIV, and ensure effective clinical care in the early stages of TB treatment.

Available only for authorised users

Statistics South Africa: Mortality and causes of death in South Africa, 2008: Findings from death notification. 2010, Statistics South Africa, Pretoria

Abdool Karim SS, Churchyard GJ, Abdool Karim Q, Lawn SD: HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. Lancet. 2009, 374: 921-933. 10.1016/S0140-6736(09)60916-8.CrossRefPubMedPubMedCentral

Lim MSC, Dowdeswell RJ, Murray J, Field N, Glynn JR, Sonnenberg P: The impact of HIV, an antiretroviral programme and tuberculosis on mortality in South African platinum miners, 1992–2010. PLoS One. 2012, 7: e38598-10.1371/journal.pone.0038598.CrossRefPubMedPubMedCentral

Corbett EL, Marston B, Churchyard GJ, De Cock KM: Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet. 2006, 367: 926-937. 10.1016/S0140-6736(06)68383-9.CrossRefPubMed

van den Broek J, Mfinanga S, Moshiro C, O'Brien R, Mugomela A, Lefi M: Impact of human immunodeficiency virus infection on the outcome of treatment and survival of tuberculosis patients in Mwanza, Tanzania. Int J Tubercul Lung Dis. 1998, 2: 547-552.

Burton JL, Underwood J: Clinical, educational, and epidemiological value of autopsy. Lancet. 2007, 369: 1471-1480. 10.1016/S0140-6736(07)60376-6.CrossRefPubMed

Connolly C, Davies GR, Wilkinson D: Impact of the human immunodeficiency virus epidemic on mortality among adults with tuberculosis in rural South Africa, 1991–1995. Int J Tubercul Lung Dis. 1998, 2: 919-925.

Harries AD, Nyangulu DS, Kang'ombe C, Ndalama D, Glynn JR, Banda H, Wirima JJ, Salaniponi FM, Liomba G, Maher D, Nunn P: Treatment outcome of an unselected cohort of tuberculosis patients in relation to human immunodeficiency virus serostatus in Zomba Hospital, Malawi. Trans R Soc Trop Med Hyg. 1998, 92: 343-347. 10.1016/S0035-9203(98)91036-7.CrossRefPubMed

Harries AD, Hargreaves NJ, Gausi F, Kwanjana JH, Salaniponi FM: High early death rate in tuberculosis patients in Malawi. Int J Tubercul Lung Dis. 2001, 5: 1000-1005.

10.

Kang'ombe CT, Harries AD, Ito K, Clark T, Nyirenda TE, Aldis W, Nunn PP, Semba RD, Salaniponi FM: Long-term outcome in patients registered with tuberculosis in Zomba, Malawi: mortality at 7 years according to initial HIV status and type of TB. Int J Tubercul Lung Dis. 2004, 8: 829-836.

11.

Kyeyune R, den Boon S, Cattamanchi A, Davis JL, Worodria W, Yoo SD, Huang L: Causes of early mortality in HIV-infected TB suspects in an East African referral hospital. J Acquir Immune Defic Syndr. 2010, 55: 446-450. 10.1097/QAI.0b013e3181eb611a.CrossRefPubMedPubMedCentral

12.

Elliott AM, Halwiindi B, Hayes RJ, Luo N, Mwinga AG, Tembo G, Machiels L, Steenbergen G, Pobee JO, Nunn P: The impact of human immunodeficiency virus on mortality of patients treated for tuberculosis in a cohort study in Zambia. Trans R Soc Trop Med Hyg. 1995, 89: 78-82. 10.1016/0035-9203(95)90668-1.CrossRefPubMed

13.

Mukadi YD, Maher D, Harries A: Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. Aids. 2001, 15: 143-152. 10.1097/00002030-200101260-00002.CrossRefPubMed

14.

Nunn P, Brindle R, Carpenter L, Odhiambo J, Wasunna K, Newnham R, Githui W, Gathua S, Omwega M, McAdam K: Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya. Analysis of early (6-month) mortality. Am Rev Respir Dis. 1992, 146: 849-854. 10.1164/ajrccm/146.4.849.CrossRefPubMed

15.

Seung KJ, Omatayo DB, Keshavjee S, Furin JJ, Farmer PE, Satti H: Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa. PLoS One. 2009, 4: e7186-10.1371/journal.pone.0007186.CrossRefPubMedPubMedCentral

16.

Waitt CJ, Squire SB: A systematic review of risk factors for death in adults during and after tuberculosis treatment. Int J Tubercul Lung Dis. 2011, 15: 871-885. 10.5588/ijtld.10.0352.CrossRef

17.

Murray J, Sonnenberg P, Shearer SC, Godfrey-Faussett P: Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. Am J Respir Crit Care Med. 1999, 159: 733-740. 10.1164/ajrccm.159.3.9804147.CrossRefPubMed

18.

Churchyard GJ, Kleinschmidt I, Corbett EL, Murray J, Smit J, De Cock KM: Factors associated with an increased case-fatality rate in HIV-infected and non-infected South African gold miners with pulmonary tuberculosis. Int J Tubercul Lung Dis. 2000, 4: 705-712.

19.

Cain KP, Anekthananon T, Burapat C, Akksilp S, Mankhatitham W, Srinak C, Nateniyom S, Sattayawuthipong W, Tasaneeyapan T, Varma JK: Causes of death in HIV-infected persons who have tuberculosis, Thailand. Emerg Infect Dis. 2009, 15: 258-264. 10.3201/eid1502.080942.CrossRefPubMedPubMedCentral

20.

Korenromp EL, Bierrenbach AL, Williams BG, Dye C: The measurement and estimation of tuberculosis mortality. Int J Tubercul Lung Dis. 2009, 13: 283-303.

21.

Sonnenberg P, Lim MSC, Dowdeswell R, Field N, Glynn JR, Murray J: Quantifying measurement errors in the estimation of tuberculosis mortality: lessons from a population of South African platinum miners. Int J Tubercul Lung Dis. 2012, 16: 1449-1454. 10.5588/ijtld.12.0086.CrossRef

22.

Mudenda V, Lucas S, Shibemba A, O'Grady J, Bates M, Kapata N, Schwank S, Mwaba P, Atun R, Hoelscher M, Maeurer M, Zumla A: Tuberculosis and Tuberculosis/HIV/AIDS-Associated Mortality in Africa: The Urgent Need to Expand and Invest in Routine and Research Autopsies. J Infect Dis. 2012, 205: s340-s346. 10.1093/infdis/jir859.CrossRefPubMed

23.

Koole O, Colebunders R: ART in low-resource settings: how to do more with less. Lancet. 2010, 376: 396-398. 10.1016/S0140-6736(10)61020-3.CrossRefPubMed

24.

Charalambous S, Grant AD, Day JH, Pemba L, Chaisson RE, Kruger P, Martin D, Wood R, Brink B, Churchyard GJ: Establishing a workplace antiretroviral therapy programme in South Africa. AIDS Care. 2007, 19: 34-41. 10.1080/09500340600677872.CrossRefPubMed

25.

Department of Health: National tuberculosis management guidelines 2008. 2009, Department of Health, Republic of South Africa, Pretoria

26.

Katzenstein A-LA: Katzenstein and Askin's Surgical Pathology of Non-Neoplastic Lung Disease. (Major Prob Pathol vol. 13). 2006, Elsevier, Edinburgh, 4

27.

World Health Organization: Global tuberculosis report 2013: Annex 1Methods, Table A1.2. 2013, WHO, Geneva

28.

Akksilp S, Karnkawinpong O, Wattanaamornkiat W, Viriyakitja D, Monkongdee P, Sitti W, Rienthong D, Siraprapasiri T, Wells CD, Tappero JW, Varma JK: Antiretroviral therapy during tuberculosis treatment and marked reduction in death rate of HIV-infected patients, Thailand. Emerg Infect Dis. 2007, 13: 1001-1007. 10.3201/eid1307.061506.CrossRefPubMedPubMedCentral

29.

Gupta A, Nadkarni G, Yang WT, Chandrasekhar A, Gupte N, Bisson GP, Hosseinipour M, Gummadi N: Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis. PLoS One. 2011, 6: e28691-10.1371/journal.pone.0028691.CrossRefPubMedPubMedCentral

30.

Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, Gengiah T, Nair G, Bamber S, Singh A, Khan M, Pienaar J, El-Sadr W, Friedland G, Abdool Karim Q: Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010, 362: 697-706. 10.1056/NEJMoa0905848.CrossRefPubMedPubMedCentral

31.

Aderaye G, Bruchfeld J, Aseffa G, Nigussie Y, Melaku K, Woldeamanuel Y, Asrat D, Worku A, Gaegziabher H, Lebaad M, Lindquist L: Pneumocystis jiroveci pneumonia and other pulmonary infections in TB smear-negative HIV-positive patients with atypical chest X-ray in Ethiopia. Scand J Infect Dis. 2007, 39: 1045-1053. 10.1080/00365540701474508.CrossRefPubMed

32.

Worodria W, Okot-Nwang M, Yoo SD, Aisu T: Causes of lower respiratory infection in HIV-infected Ugandan adults who are sputum AFB smear-negative. Int J Tubercul Lung Dis. 2003, 7: 117-123.

33.

Martinson NA, Karstaedt A, Venter WD, Omar T, King P, Mbengo T, Marais E, McIntyre J, Chaisson RE, Hale M: Causes of death in hospitalized adults with a premortem diagnosis of tuberculosis: an autopsy study. AIDS. 2007, 21: 2043-2050. 10.1097/QAD.0b013e3282eea47f.CrossRefPubMed

34.

Lowrance D, Makombe S, Harries A, Yu J, Aberle-Grasse J, Eiger O, Shiraishi R, Marston B, Ellerbrock T, Libamba E: Lower early mortality rates among patients receiving antiretroviral treatment at clinics offering cotrimoxazole prophylaxis in Malawi. J Acquir Immune Defic Syndr. 2007, 46: 56-61.PubMed

35.

Hoffmann CJ, Fielding KL, Charalambous S, Innes C, Chaisson RE, Grant AD, Churchyard GJ: Reducing mortality with cotrimoxazole preventive therapy at initiation of antiretroviral therapy in South Africa. Aids. 2010, 24: 1709-1716. 10.1097/QAD.0b013e32833ac6bc.CrossRefPubMedPubMedCentral

36.

Wiktor SZ, Sassan-Morokro M, Grant AD, Abouya L, Karon JM, Maurice C, Djomand G, Ackah A, Domoua K, Kadio A, Yapi A, Combe P, Tossou O, Roels TH, Lackritz EM, Coulibaly D, De Cock KM, Coulibaly IM, Greenberg AE: Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomised controlled trial. Lancet. 1999, 353: 1469-1475. 10.1016/S0140-6736(99)03465-0.CrossRefPubMed

37.

Jonnalagada S, Harries AD, Zachariah R, Satyanarayana S, Tetali S, Keshav Chander G, Rao S, Rao R, Peri S, Anchala R, Kannuri NK: The timing of death in patients with tuberculosis who die during anti-tuberculosis treatment in Andhra Pradesh, South India. BMC Public Health. 2011, 11: 921-10.1186/1471-2458-11-921.CrossRefPubMedPubMedCentral

38.

Chaisson RE, Churchyard GJ: Recurrent tuberculosis: relapse, reinfection, and HIV. J Infect Dis. 2010, 201: 653-655. 10.1086/650531.CrossRefPubMedPubMedCentral

39.

Glynn JR, Warndorff DK, Fine PE, Munthali MM, Sichone W, Ponnighaus JM: Measurement and determinants of tuberculosis outcome in Karonga District, Malawi. Bull World Health Organ. 1998, 76: 295-305.PubMedPubMedCentral

40.

Field N, Murray J, Wong ML, Dowdeswell R, Dudumayo N, Rametsi L, Martinson N, Lipman M, Glynn JR, Sonnenberg P: Missed opportunities in TB diagnosis: a TB Process-Based Performance Review tool to evaluate and improve clinical care. BMC Public Health. 2011, 11: 127-10.1186/1471-2458-11-127.CrossRefPubMedPubMedCentral

41.

Cowie RL: The epidemiology of tuberculosis in gold miners with silicosis. Am J Respir Crit Care Med. 1994, 150: 1460-1462. 10.1164/ajrccm.150.5.7952577.CrossRefPubMed

42.

Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godrey-Faussett P: HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet. 2001, 357: 890-

Title: Timing, rates, and causes of death in a large South African tuberculosis programme
Authors: Nigel Field
Megan SC Lim
Jill Murray
Robert J Dowdeswell
Judith R Glynn
Pam Sonnenberg
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: BMC Infectious Diseases / Issue 1/2014
Electronic ISSN: 1471-2334
DOI: https://doi.org/10.1186/s12879-014-0679-9

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Timing, rates, and causes of death in a large South African tuberculosis programme

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2014

A randomized controlled phase IIb wound healing trial of cutaneous leishmaniasis ulcers with 0.045% pharmaceutical chlorite (DAC N-055) with and without bipolar high frequency electro-cauterization versus intralesional antimony in Afghanistan

Significance of serum procalcitonin as biomarker for detection of bacterial peritonitis: a systematic review and meta-analysis

Community-onset bloodstream infection with multidrug-resistant organisms: a matched case-control study

Feasibility and impact of an intensified antibiotic stewardship programme targeting cephalosporin and fluoroquinolone use in a tertiary care university medical center

A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study

Persistence, clearance and reinfection regarding six high risk human papillomavirus types in Colombian women: a follow-up study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page